A new trading day began on Tuesday, with Olema Pharmaceuticals Inc (NASDAQ: OLMA) stock price up 3.02% from the previous day of trading, before settling in for the closing price of $11.94. OLMA’s price has ranged from $8.51 to $17.79 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 22.72%. With a float of $49.24 million, this company’s outstanding shares have now reached $54.99 million.
Let’s determine the extent of company efficiency that accounts for 74 employees.
Olema Pharmaceuticals Inc (OLMA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Olema Pharmaceuticals Inc is 14.02%, while institutional ownership is 87.95%. The most recent insider transaction that took place on Aug 01 ’24, was worth 35,796,000. In this transaction 10% Owner of this company sold 2,400,000 shares at a rate of $14.91, taking the stock ownership to the 783,118 shares. Before that another transaction happened on Jul 29 ’24, when Company’s Director sold 4,066 for $15.58, making the entire transaction worth $63,348. This insider now owns 752,217 shares in total.
Olema Pharmaceuticals Inc (OLMA) Recent Fiscal highlights
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.48 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.63 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.72% per share during the next fiscal year.
Olema Pharmaceuticals Inc (NASDAQ: OLMA) Trading Performance Indicators
Here are Olema Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.06, a number that is poised to hit -0.58 in the next quarter and is forecasted to reach -2.58 in one year’s time.
Technical Analysis of Olema Pharmaceuticals Inc (OLMA)
Looking closely at Olema Pharmaceuticals Inc (NASDAQ: OLMA), its last 5-days average volume was 0.36 million, which is a drop from its year-to-date volume of 0.8 million. As of the previous 9 days, the stock’s Stochastic %D was 15.94%. Additionally, its Average True Range was 0.74.
During the past 100 days, Olema Pharmaceuticals Inc’s (OLMA) raw stochastic average was set at 46.73%, which indicates a significant increase from 30.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.67% in the past 14 days, which was lower than the 77.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.85, while its 200-day Moving Average is $12.25. However, in the short run, Olema Pharmaceuticals Inc’s stock first resistance to watch stands at $12.57. Second resistance stands at $12.83. The third major resistance level sits at $13.32. If the price goes on to break the first support level at $11.82, it is likely to go to the next support level at $11.33. Now, if the price goes above the second support level, the third support stands at $11.07.
Olema Pharmaceuticals Inc (NASDAQ: OLMA) Key Stats
With a market capitalization of 704.42 million, the company has a total of 55,934K Shares Outstanding. Currently, annual sales are 0 K while annual income is -96,660 K. The company’s previous quarter sales were 0 K while its latest quarter income was -30,380 K.
